However, mice heterozygous for DNA2 loss-of function mutations are viable, which suggests that there is a therapeutic window to inhibit DNA2 activity in the context of cancers with DNA2 overexpression, such as MM that has relapsed after PI-based treatment27. Here, DNA2 is linked to Miyoshi myopathy.